FDA May Be Catching Up With FDAAA Workload, Latest Performance Data Suggests
Executive Summary
Preliminary FDA data indicate the agency may be catching up with the workload imposed by the FDA Amendments Act, with the agency reporting it could meet 10 of 12 review performance goals for NDAs and BLAs submitted in fiscal 2009.
You may also be interested in...
Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13
Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.